Cover Image

TxCell SA : 產品平台分析

TxCell SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251730
出版日期 內容資訊 英文 24 Pages
Back to Top
TxCell SA : 產品平台分析 TxCell SA - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 24 Pages



Txcell SA是藉由抗原特異性增殖控制性T-細胞增生,來開發發炎性疾病和自體免疫疾病之免疫療法的生物企業。

本報告提供TxCell SA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

TxCell SA的基本資料

  • TxCell SA概要
  • 主要資訊
  • 企業資料

TxCell SA:R&D概要

  • 主要的治療範圍

TxCell SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

TxCell SA:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

TxCell SA:藥物簡介

  • Col-Treg
  • Des-Treg
  • HSP60-Treg
  • Myelin-Treg

TxCell SA:開發平台分析

  • 各給藥途徑
  • 各分子類型

TxCell SA:最近的開發平台趨勢

TxCell SA:暫停中的計劃

TxCell SA:總公司和子公司的所在地



Product Code: GMDHC07378CDB


Global Markets Direct's, 'TxCell SA - Product Pipeline Review - 2015', provides an overview of the TxCell SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TxCell SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of TxCell SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of TxCell SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the TxCell SA's pipeline products

Reasons to buy

  • Evaluate TxCell SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of TxCell SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the TxCell SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of TxCell SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of TxCell SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of TxCell SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TxCell SA Snapshot
    • TxCell SA Overview
    • Key Information
    • Key Facts
  • TxCell SA - Research and Development Overview
    • Key Therapeutic Areas
  • TxCell SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • TxCell SA - Pipeline Products Glance
    • TxCell SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • TxCell SA - Drug Profiles
    • Col-Treg
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Des-Treg
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSP60-Treg
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myelin-Treg
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TxCell SA - Pipeline Analysis
    • TxCell SA - Pipeline Products by Route of Administration
    • TxCell SA - Pipeline Products by Molecule Type
  • TxCell SA - Recent Pipeline Updates
  • TxCell SA - Dormant Projects
  • TxCell SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TxCell SA, Key Information
  • TxCell SA, Key Facts
  • TxCell SA - Pipeline by Indication, 2015
  • TxCell SA - Pipeline by Stage of Development, 2015
  • TxCell SA - Monotherapy Products in Pipeline, 2015
  • TxCell SA - Out-Licensed Products in Pipeline, 2015
  • TxCell SA - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • TxCell SA - Preclinical, 2015
  • TxCell SA - Discovery, 2015
  • TxCell SA - Pipeline by Route of Administration, 2015
  • TxCell SA - Pipeline by Molecule Type, 2015
  • TxCell SA - Recent Pipeline Updates, 2015
  • TxCell SA - Dormant Developmental Projects,2015

List of Figures

  • TxCell SA - Pipeline by Top 10 Indication, 2015
  • TxCell SA - Pipeline by Stage of Development, 2015
  • TxCell SA - Monotherapy Products in Pipeline, 2015
  • TxCell SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top